_256_384.jpg)
Drug Approval | April 27, 2026
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The deal signals a clear push to expand access to care in underserved regions
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
Subscribe To Our Newsletter & Stay Updated
